Margo J van Campenhout

9PUBLICATIONS
12CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsRegenerative medicine (incl. stem cells)Cardiology (incl. cardiovascular diseases)HaematologyEnvironmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 19, 2024
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).

Mina S Farag, Margo J H van Campenhout, M J Sonneveld

|Nov 22, 2020
Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.

Sylvia M Brakenhoff, Robert A de Man, André Boonstra

|Feb 14, 2020
Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B.

Margo J H van Campenhout, Florian van Bömmel, Maria Pfefferkorn

|Dec 13, 2019
Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts.

Alan J Mueller-Breckenridge, Fernando Garcia-Alcalde, Steffen Wildum

|May 29, 2019
Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B.

Margo J H van Campenhout, Vincent Rijckborst, Willem Pieter Brouwer

|Mar 22, 2019
Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues.

Milan J Sonneveld, Gertine W van Oord, Margo J van Campenhout

Pageof 2

Frequent Collaborators

4 joint publications

Willem Pieter Brouwer

4 joint publications

André Boonstra

3 joint publications

Milan J Sonneveld

2 joint publications

Kin Seng Liem